The performance of companies tied to Viagra's history presents a intricate investment picture . While the initial boom generated substantial gains, generic alternatives have significantly diminished sales . Investing in related pharmaceutical companies now requires a discerning assessment of proprietary protection , evolving healthcare trends , and